Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • c-RET
    (3)
  • Raf
    (1)
  • S6 Kinase
    (1)
  • Src
    (1)
  • Others
    (2)
Filter
Search Result
Results for "

ret v804l

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    5
    TargetMol | Inhibitors_Agonists
AD80
T43011384071-99-1
AD80, a multikinase inhibitor, targets RET, RAF, SRC, and S6K with significantly reduced activity on mTOR.
  • Inquiry Price
Size
QTY
RET-IN-16
T732562259657-48-0
RET-IN-16 is a potent, selective inhibitor of RET, exhibiting IC50 values of 3.98 nM for RET(WT), 8.42 nM for RET(M918T), 15.05 nM for RET(V804L), 7.86 nM for RET(V804M), 5.43 nM for RET-CCDC6, and 8.86 nM for RET-KIF5B, indicating its high efficacy across different RET mutations. It possesses anticancer properties.
  • Inquiry Price
6-8 weeks
Size
QTY
RET-IN-23
T790992479961-46-9
RET-IN-23 is an orally available and highly potent RET inhibitor with significant antitumor activity for the study of non-small cell lung cancer.
  • Inquiry Price
6-8 weeks
Size
QTY
Pralsetinib
Blu667
TQ02772097132-94-8
Pralsetinib (Blu667) (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion).
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Pralsetinib HCl (2097132-94-8 free base)
Pralsetinib HCl,Pralsetinib hydrochloride,BLU-667,BLU667,BLU 667
TQ0277L
Pralsetinib is a selective and next-generation RET inhibitor (IC50: 0.3-0.4 nM for WT RET, RET mutants V804L, V804M, M918T, and CCDC6-RET fusion). BLU-667 is an effective and selective inhibitor of RET mutations, fusions, and predicted resistant mutants.
  • Inquiry Price
Size
QTY